Evidence map›Paper›PMID 30460342›Full record

ReviewAnnals of gastroenterological surgery2018

Recent updates in perioperative chemotherapy and recurrence pattern of gastric cancer.

Shingo Kanaji, Satoshi Suzuki, Yoshiko Matsuda, Hiroshi Hasegawa, Masashi Yamamoto, Kimihiro Yamashita, Taro Oshikiri, Takeru Matsuda, Tetsu Nakamura, Yasuo Sumi and 1 more

Registry-linked trialOpen access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Annals of gastroenterological surgery, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05351398 (The Clinical Efficacy of Patient-derived Organoid-based Drug Sensitive Neoadjuvant Chemotherapy Versus Traditional Neoadjuvant Chemotherapy in Advanced Gastric Cancer), which is not on this map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05351398 unknown statusnot on this mapstarted 2022, after this paper: background citation

The Clinical Efficacy of Patient-derived Organoid-based Drug Sensitive Neoadjuvant Chemotherapy Versus Traditional Neoadjuvant Chemotherapy in Advanced Gastric Cancer: a Prospective Multi-center Randomized Controlled Study

TypeobservationalSponsorShanghai Minimally Invasive Surgery CenterRan2022 to 2023Enrolled54ConditionsAdvanced Gastric CarcinomaArmsPDO group, Traditional group
3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 30 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. LRRC8A influences the growth of gastric cancer cells via the p53 signaling pathway.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2021
    Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Surgery: To what extent can we operate?Annals of gastroenterological surgery · 2018
    Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Shingo KanajiDivision of Gastrointestinal Surgery Department of Surgery Kobe University Graduate School of Medicine Kobe Japan.ORCID 0000-0002-8698-8923
Satoshi SuzukiDivision of Gastrointestinal Surgery Department of Surgery Kobe University Graduate School of Medicine Kobe Japan.ORCID 0000-0002-7287-6998
Yoshiko MatsudaDivision of Gastrointestinal Surgery Department of Surgery Kobe University Graduate School of Medicine Kobe Japan.
Hiroshi HasegawaDivision of Gastrointestinal Surgery Department of Surgery Kobe University Graduate School of Medicine Kobe Japan.
Masashi YamamotoDivision of Gastrointestinal Surgery Department of Surgery Kobe University Graduate School of Medicine Kobe Japan.
Kimihiro YamashitaDivision of Gastrointestinal Surgery Department of Surgery Kobe University Graduate School of Medicine Kobe Japan.
Taro OshikiriDivision of Gastrointestinal Surgery Department of Surgery Kobe University Graduate School of Medicine Kobe Japan.
Takeru MatsudaDivision of Minimally Invasive Surgery Department of Surgery Kobe University Graduate School of Medicine Kobe Japan.
Tetsu NakamuraDivision of Gastrointestinal Surgery Department of Surgery Kobe University Graduate School of Medicine Kobe Japan.
Yasuo SumiDivision of International Clinical Cancer Research Department of Surgery Kobe University Graduate School of Medicine Kobe Japan.
Yoshihiro KakejiDivision of Minimally Invasive Surgery Department of Surgery Kobe University Graduate School of Medicine Kobe Japan.ORCID 0000-0002-2727-0241
Kobe University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gastrectomy with D2 lymph node dissection has become the global standard procedure for locally advanced gastric cancer to maximally reduce locoregional recurrence. In East Asia, based on the evidence of the ACTS-GC and the CLASSIC trials, postadjuvant chemotherapy with S-1 monotherapy or capecitabine and oxaliplatin after curative D2 gastrectomy is the current standard strategy. However, approximately 20% to 30% of patients still develop distant recurrence even after these postadjuvant chemotherapies, especially in those with pathological stage III disease. This review summarizes recent (2008-2018) evidence on the benefits of adjuvant therapy for locally advanced gastric cancer. JACRO GC-07, a Phase III trial, recently showed a superior 3-year recurrence-free survival of the S-1 plus docetaxel regimen in comparison to S-1 monotherapy for patients with pathological stage III gastric cancer after curative D2 gastrectomy. With regard to recent new evidence on neoadjuvant strategy, JCOG0501, a Phase III trial, did not show any superiority in 3-year overall survival (OS) of additional neoadjuvant chemotherapy with S-1/cisplatin over postadjuvant S-1 monotherapy in scirrhous type gastric cancer. Further clinical trials of neoadjuvant chemotherapy are ongoing to improve the poor prognosis for gastric cancer with extensive lymph node metastases. These trials could lead to new evidence for improved treatment of gastric cancer in the near future.

Indexed as

D2 lymph node dissectiongastric cancerneoadjuvant chemotherapyperiadjuvant chemotherapypostadjuvant chemotherapyrecurrence pattern

Identifiers

PMID30460342
PMCPMC6236108
OpenAlexW2889519980

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.